ROCKVILLE, Md., Aug. 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has launched next generation sequencing (NGS) services in the U.S. that were developed by its subsidiary, Ares Genetics (“Ares”), which strives to become a leader in bacterial genomics and artificial intelligence (AI)-powered antimicrobial resistance (AMR) solutions.

More:
OpGen Launches Ares Sequencing Services in the U.S. from its Rockville, Maryland Laboratory

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced the appointment of Mark Dizon, J.D., to the position of general counsel.

Here is the original post:
Frontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General Counsel

Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis

The rest is here:
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England...

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.

Read the original post:
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials

Read the original:
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

Originally posted here:
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium

Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunction

See original here:
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels...

SAN CLEMENTE, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced its live and in-person participation at the 5CC World (5-Continent-Congress) that is being held from September 1-4, in Barcelona, Spain.

See the original post:
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and...

BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for?gastrointestinal diseases, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. First Wave’s common stock will continue to be traded on the NASDAQ Capital Market under the symbol FWBI and will begin trading on a split-adjusted basis when the market opens on Friday, August 26, 2022, under a new CUSIP number, 33749P200.

See more here:
First Wave BioPharma, Inc. Announces Reverse Stock Split

NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET

See the rest here:
MDxHealth Reports Half Year 2022 Results

ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce it is in full compliance with OTC Markets following the filing of its 10-Q allowing removal of the delinquency flag and a return to Current Information status with the OTC Markets Group. New management, moving forward, will ensure the company continues to stay in full compliance with all OTC Markets reporting standards bringing confidence to the public.

Original post:
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board

Read the original post:
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted expanded coverage for the use of Myriad’s BRACAnalysis® Diagnostic System as a companion diagnostic to identify patients with germline BRCA-mutated (gBRCAm) and HER2-negative high-risk recurrent breast cancer who may benefit from Lynparza®(olaparib).

Continued here:
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in...

Significant Milestones Achieved Significant Milestones Achieved

View post:
Kane Biotech Announces Second Quarter 2022 Financial Results

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited (“Takeda”). Following a review of its pipeline, Takeda informed Finch of its decision to terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.

Continued here:
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of cognitive function from the Company’s ongoing longitudinal natural history study of people living with classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism Annual Symposium in Freiburg, Germany, August 30 – September 2, 2022. Data exploring genomic population-based estimates of the incidence of HCU will also be presented. The Company is currently advancing a novel investigational enzyme replacement therapy, pegtibatinase, for the treatment of HCU.

See more here:
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA -- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA

Go here to see the original:
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted.

Originally posted here:
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.

See the original post here:
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

REGULATED INFORMATION

Visit link:
Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022